NMN vs NAD+: What the Evidence Actually Shows

NMN and NAD+ get compared as though they were two brands of the same thing — one a little upstream of the other, both "raising your NAD+." The chemistry does line up that way: NMN (nicotinamide mononucleotide) is one metabolic step before NAD+ (nicotinamide adenine dinucleotide), and the body converts it. But the useful comparison is not biochemical. It is that these two have been studied in almost opposite ways, and once you line the two trial records up side by side, the question "which one is better" turns out to be the wrong question.

NMN has been tested the way it is sold: swallowed, in small randomized trials, with real endpoints — and with a genuine, unresolved argument running underneath about whether it survives digestion intact at all. NAD+ has mostly been tested the way it is not sold to consumers, and the injectable and intravenous forms that clinics and telehealth providers actually sell have almost no outcome evidence of any kind.

They are not two versions of one product

NAD+ is the coenzyme itself — the molecule every cell uses for energy metabolism and DNA repair, and the one whose age-related decline is the entire premise of this category⁵. NMN is a precursor: a smaller molecule the body's own salvage pathway converts into NAD+.

The commercial pitch for selling the precursor instead of the destination is that a smaller, differently charged molecule ought to cross membranes and survive the gut more easily than NAD+ itself. That is a reasonable-sounding premise. Whether it is true is the subject of a real scientific fight, covered below.

The commercial pitch for selling NAD+ itself is different: skip the conversion entirely by putting NAD+ straight into a vein or under the skin. That premise is also reasonable-sounding. It has been tested even less.

The asymmetry that matters

Here is the part that gets lost when these two are compared feature-by-feature.

A 2026 PRISMA-guided systematic review screened the NAD-compound literature — 113 eligible studies, 33 of them human, spanning January 2010 to October 2025 — and reported in its own results text that "no eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications"¹. Not "weak evidence." Not "mixed results." No eligible outcome trials at all, for the exact form sold by the clinics and telehealth providers marketing it.

The one human study of directly infused NAD+ that exists is a pharmacokinetic pilot, not an outcome trial — and it is worth reading closely, because it did not go smoothly. During a six-hour intravenous NAD+ infusion, the researchers reported that "no change in plasma [NAD+] or metabolites... were observed until after 2 h"². The flagship human study of injected NAD+ struggled to demonstrate a prompt, clear rise in the very thing it was infusing.

NMN's record is thinner than its marketing but it is not empty in the same way. It has small randomized human trials with actual endpoints: a 2021 trial in prediabetic women reporting improved muscle insulin sensitivity⁶, a 2020 Japanese trial of oral administration measuring clinical parameters⁹, and a 2026 review of safety and metabolism-related outcomes across the oral literature¹⁰.

That is the honest comparison. One has contested evidence. The other has, for the form being sold, close to none.

The absorption dispute underneath every NMN claim

This is the part of the NMN story that a supplement page will not tell you, and it is unresolved.

In 2019, a team led by Shin-ichiro Imai published in Nature Metabolism identifying Slc12a8 as a dedicated intestinal transporter for NMN — a specific molecular gate that would let intact NMN cross the gut wall rather than being broken down first and reassembled later¹¹. In the same journal, the same year, a different lab published a direct rebuttal titled, plainly, "Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter"¹². The original authors replied defending the finding. The disagreement was never definitively settled in the literature located here.

That matters because the transporter is the mechanism proponents cite for why swallowing NMN should work at all. If NMN is simply degraded and reassembled like any other nicotinamide-pathway precursor, then a great deal of the marketing distinction between NMN and cheaper precursors collapses.

The most-cited NMN trial, and the challenge to it

The 2021 prediabetic-women trial is the single study most often pointed to as proof NMN works⁶. It also drew a formal published comment from Charles Brenner — the same researcher behind the transporter rebuttal — raising a methodological objection⁷, and the original authors published a response⁸.

Two separate, formally published challenges to two separate NMN claims, from the same critic, is a real and checkable pattern. It does not mean NMN does nothing. It means the evidence base is actively contested by people who work in it, which is a materially different situation from "proven."

What this means if you are actually choosing

If you are choosing between a bottle of NMN capsules and an NAD+ injection or drip, the evidence does not hand you a winner. It hands you two different kinds of uncertainty:

• •Oral NMN has small human trials with real endpoints, an unresolved dispute about whether it is absorbed intact, and a formal challenge to its headline trial.
• •Injected or infused NAD+ has no eligible outcome trials at all for that route, one pharmacokinetic pilot that struggled to show a fast plasma rise, and two independent 2026 reviews concluding it should be treated as experimental rather than evidence-based⁴⁵.

There is one more asymmetry worth knowing: tolerability. A retrospective study at a commercial IV-therapy chain compared NAD+ infusions against nicotinamide riboside infusions and found NAD+ recipients reported "moderate to severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions" — symptoms severe enough that the drip had to be slowed, with NAD+ infusions averaging 97 minutes against 37 for the comparison³. Whatever else is unsettled, the injected route is measurably less comfortable.

And the best-designed randomized trial anywhere in this literature — a genuine Phase 2 factorial RCT published in The Lancet Neurology — studied an oral NAD+ precursor combined with exercise in Friedreich's ataxia, a rare disease¹³. Even there, the positive finding belonged to the combination arm. The strongest study in the field is not about the product either of these categories sells.

What nobody has tested

No head-to-head randomized trial of oral NMN against injected NAD+ exists. Every comparison you will read, including this one, is an assembly of separate literatures that were never designed to be compared. Anyone telling you which is definitively better is telling you something the trial record does not support.

If you want the deeper record on either half of this comparison, the two evidence reviews behind this page go further: the NAD+ evidence review covers the injectable literature and the regulatory picture in full, and the NMN evidence review covers the absorption dispute and the supplement-legality rollercoaster. For what the dosing literature does and does not establish, see NAD+ dosage and side effects. And if you are pricing the injectable form, our NAD+ provider comparison lists what each seller actually charges and which name a pharmacy. Both compounds are routinely sold as peptides and neither is one — our explainer on whether NAD+ is a peptide covers the structural difference and the practical reasons the distinction matters.